Roche Q1 sales up 10%, confirms 2022 outlook
Send a link to a friend
[April 25, 2022]
By Ludwig Burger
(Reuters) -Swiss drugmaker Roche's first
quarter sales rose a better-than-expected 10% on strong U.S. demand for
rapid COVID-19 antigen tests and drugs including Ocrevus against
multiple sclerosis as well as Hemlibra against haemophilia.
Quarterly sales rose to 16.44 billion Swiss francs ($17.17 billion), up
from 14.93 billion Swiss francs in the year-earlier period, the company
said on Monday. That was slightly above a market consensus of about 16
billion francs.
The diagnostics division accounted for most of the positive surprise,
reporting sales growth of 24% to 5.3 billion francs on usage of its
COVID-19 tests and cardiac tests.
Roche reiterated that it expected currency-adjusted 2022 sales to be
flat or grow in the low-single-digit percentage range, below last year's
9% gain.
![](http://archives.lincolndailynews.com/2022/Apr/25/images/ads/current/farmers_bank_sda_SFARM_2022.png)
[to top of second column]
|
![](../images/042522pics/health7.jpg)
The logo of Swiss drugmaker Roche is seen at its headquarters in
Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann
![](http://archives.lincolndailynews.com/2022/Apr/25/images/ads/current/graue_21BLAZER_081621.png)
It also reaffirmed that sales of COVID-19 medicines and diagnostics
would decrease by about 2 billion Swiss francs this year to around 5
billion francs.
Ocrevus revenue gained 18% to reach 1.45 billion francs and Hemlibra
sales jumped 30% to 853 million francs, offsetting a decline in
established off-patent cancer medicines Herceptin, Avastin and Rituxan
due to cheaper rival products.
($1 = 0.9577 Swiss francs)
(Reporting by Ludwig BurgerEditing by Miranda Murray)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |